Jazz Pharmaceuticals
Clinical trials sponsored by Jazz Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on neuroscience and oncology treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors Results expected Sep 2026 (estimated)
- New antibody drug targets HER2 cancers in broad trial Results expected Dec 2026 (estimated)
- CBD epilepsy drug under Real-World watch for rare seizure disorders Results expected Feb 2027 (estimated)
- First human test of JZP269: can this experimental drug pass the safety check? Results expected Feb 2027 (estimated)
- Epidiolex liver check: is Long-Term use safe? Results expected Aug 2027 (estimated)
-
New drug JZP815 targets tough cancers in early trial
Disease control OngoingThis early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors
Disease control OngoingThis study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
CBD epilepsy drug under Real-World watch for rare seizure disorders
Disease control OngoingThis study follows about 111 people with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex who are taking Epidyolex (a CBD oral solution) for seizures. Researchers track how many stay on the drug for a year and how many seizure-free days they have. It's an o…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Epidiolex liver check: is Long-Term use safe?
Knowledge-focused OngoingThis study follows 154 people taking Epidiolex (cannabidiol) for seizures caused by Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will monitor for signs of chronic liver injury and fibrosis over time using blood tests and liver scans. The go…
Phase 4 • Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC